Overview India’s MedTech industry was valued at roughly US$12 billion in 2023–24 and is projected to reach about US$50 billion by 2030. Strong growth masks persistent supply chain weaknesses. The Indian MedTech supply chain faces interlocking challenges, regulatory and procurement mismatches, exclusionary tender rules, and ambiguous refurbished import policies amplified by geopolitical disruption, infrastructure gaps, and capability shortfalls.
The Triangle Trap: Core supply chain failures
Public procurement bias and certification mismatch
Procurement often favors products with US FDA or CE marks, making these standards de facto gatekeepers. Many domestic manufacturers lack the documentation, audit systems, or resources to secure these certifications, reducing participation in large tenders and constricting the Indian medical device supply chain.
Global Tender Enquiry (GTE) exclusions and market distortion
GTE rules meant to preserve national interest have sometimes excluded domestic suppliers. The Department of Expenditure’s designation of 354 excluded devices through 2027 demonstrates how procurement policy can unintentionally lock Indian vendors out of important opportunities, undermining local competitiveness.
Ambiguous refurbished import policy
Conflicting guidance between the Ministry of Environment, Forest and Climate Change (MoEFCC) permitting non hazardous imports and CDSCO’s 2025 restriction on refurbished CT, MRI, and cath lab imports creates market uncertainty. Hospitals and diagnostic chains face constrained access to affordable capital equipment when refurbished device rules remain unclear.
Geopolitical and cost pressures
Tensions in West Asia and disruptions to routes such as the Strait of Hormuz have driven up freight, fuel, and insurance costs. Equipment prices have risen an estimated 15–20% in many cases, squeezing hospital budgets and increasing healthcare costs for patients — a direct impact on the MedTech supply chain India wide.
Structural weaknesses: Skills, Fragmentation, cold chain
India’s MedTech market is fragmented, with many small vendors lacking quality systems, regulatory know how, and distribution scale. Weak cold chain and warehousing infrastructure — particularly in rural and semi rural areas — increases waste and compromises access to temperature sensitive devices and consumables.
Consequences for providers and patients
-
Higher capital and operating costs for hospitals and diagnostic centers.
-
Reduced local manufacturing investment and slower adoption of innovation.
-
Supply intermittency and geographic inequities in device access.
-
Increased out of pocket costs for patients.
Priority policy and operational fixes
Harmonize certification pathways
Create a tiered compliance roadmap that helps Indian manufacturers progress toward international standards, supported by subsidized pre audit assistance and shared public testing labs.
Rationalize GTE and procurement rules
Revisit excluded device lists, design procurement to reward localization and lifecycle cost, and enable procurement aggregation to help smaller suppliers scale.
Unify refurbished device policy
Publish a single national framework setting refurbishment standards, traceability, safety checks, and conditional import criteria for second hand diagnostic assets.
Invest in logistics and cold chain
Prioritize regional cold chain hubs, encourage public private partnerships (PPPs), and deploy real time temperature monitoring to secure last mile delivery to underserved regions.
Stabilize tariff and corridor policies
Lock in customs schedules for critical inputs and align tariff policy with a MedTech industrial roadmap offering finance, skills training, and quality infrastructure.
Quick win: MedTech Compliance Hub
A government backed MedTech Compliance Hub offering subsidized gap assessments, pre audit remediation, and an international certification mentorship program could help dozens of small manufacturers obtain export grade credentials within 12–18 months, easing procurement bottlenecks.
Closing note
Solving these supply chain issues requires coordinated policy reform, targeted infrastructure investment, and practical programs to raise compliance and scale among domestic firms. Doing so will reduce costs, widen access, and help India capture the projected growth in the MedTech sector by 2030.